The biotechnology company Hansa Biopharma falls 26 percent after the company, among other things, postponed the schedule for the phase 3 study Confides. The company now expects that the randomization of patients will be completed in mid-2024, compared to the previous target of H2 2023.
Furthermore, the company predicts that an approval application can be submitted in 2025, instead of 2024. Hansa Biopharma has also presented preliminary sales figures for the third quarter. Revenue is expected to amount to SEK 22.8 million, of which SEK 16.5 million comes from product sales.
Redeye will lower its estimates, according to a comment from the research house. The sharp fall in the stock is partly understandable, notes Redeye. The Confides study examines the substance imlifidase, which is used in kidney transplantation.